Immunitybio

IBRX · NASDAQ

$8.77+$0.35 (+4.16%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $8.42

Latest news

NewsOct 19, 11:52 AM ETVandana Singh
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
Press releaseOct 16, 11:49 AM ETBusiness Wire
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
NewsOct 15, 7:01 AM ETDylan Berman
ImmunityBio Stock Climbs Thursday: What's Going On?
Press releaseOct 14, 4:18 PM ETBusiness Wire
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
NewsOct 14, 1:58 PM ETVandana Singh
Why Is ImmunityBio Stock Gaining Wednesday?
NewsOct 9, 10:51 AM ETAvi Kapoor
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Press releaseOct 8, 8:30 AM ETBusiness Wire
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
NewsOct 2, 1:20 PM ETEvette Mitkov
ImmunityBio Stock Jumps: What's Going On?
Press releaseOct 2, 11:44 AM ETGlobe Newswire
These High-Voltage Stocks Are Suddenly Impossible to Ignore
Press releaseOct 1, 7:00 AM ETPRNewswire
HLS Therapeutics Announces Board of Directors Changes
Press releaseSep 14, 10:30 AM ETGlobe Newswire
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Press releaseAug 10, 9:00 AM ETBusiness Wire
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
Press releaseAug 4, 7:30 AM ETBusiness Wire
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
NewsJul 30, 1:20 PM ETVandana Singh
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
NewsJul 30, 4:14 AM ET
Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients
Press releaseJul 29, 6:45 PM ETBusiness Wire
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
NewsJul 13, 2:29 PM ETErica Kollmann
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
NewsJun 17, 7:50 AM ETAvi Kapoor
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'
Press releaseJun 8, 9:01 AM ETGlobe Newswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Press releaseJun 3, 9:28 AM ETGlobe Newswire
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
Press releaseJun 1, 1:51 PM ETBusiness Wire
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Press releaseMay 29, 9:00 AM ETPRNewswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
Press releaseMay 26, 4:00 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
Press releaseMay 26, 1:27 PM ETBusiness Wire
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Press releaseMay 26, 9:00 AM ETPRNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX
Press releaseMay 26, 8:56 AM ETBusiness Wire
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Press releaseMay 26, 4:52 AM ETPRNewswire
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman
Press releaseMay 25, 11:05 AM ETGlobe Newswire
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
Press releaseMay 23, 7:37 PM ETPRNewswire
IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Press releaseMay 22, 5:25 PM ETBusiness Wire
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
Press releaseMay 22, 4:05 PM ETGlobe Newswire
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
Press releaseMay 22, 1:09 PM ETPRNewswire
Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Press releaseMay 22, 12:48 PM ETGlobe Newswire
IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman
NewsMay 20, 10:02 AM ETAvi Kapoor
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
NewsMay 20, 8:49 AM ETVandana Singh
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
NewsMay 19, 12:57 PM ETVandana Singh
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
NewsMay 18, 10:20 AM ETVandana Singh
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
NewsMay 7, 1:53 PM ETVandana Singh
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
Press releaseMay 4, 10:18 PM ETGlobe Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
NewsApr 9, 2:11 PM ETVandana Singh
Why Is ImmunityBio Stock Rallying Thursday?
NewsApr 6, 11:14 AM ETVandana Singh
FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes
NewsMar 31, 12:48 PM ETAlex Perry
Why Are ImmunityBio Shares Rising Today?
NewsMar 24, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsJan 20, 12:29 PM ETAvi Kapoor
Crude Oil Gains 2%; D.R. Horton Earnings Top Views

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

ImmunityBio Stock Climbs Thursday: What's Going On?

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Why Is ImmunityBio Stock Gaining Wednesday?

Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

ImmunityBio Stock Jumps: What's Going On?

These High-Voltage Stocks Are Suddenly Impossible to Ignore

HLS Therapeutics Announces Board of Directors Changes

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now

Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

The $13 Million Company Teaching the Immune System to Hunt Cancer

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky

Why Is ImmunityBio Stock Rallying Thursday?

FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes

Why Are ImmunityBio Shares Rising Today?

12 Health Care Stocks Moving In Tuesday's Intraday Session

Crude Oil Gains 2%; D.R. Horton Earnings Top Views